SCHEMBL5535857

SCHEMBL5535857

CCC(=O)Nc1cccc([O])c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.69
POLB P06746 2/20 0.69
NR4A1 P22736 1/20 0.69
GAA P10253 2/20 0.67
KMT2A Q03164 5/20 0.63
MEN1 O00255 3/20 0.63
LMNA P02545 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
F2R P25116 1/20 0.59
CYP3A4 P08684 4/20 0.56
CYP2C19 P33261 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
CYP2D6 P10635 2/20 0.56
MAPT P10636 2/20 0.56
ALDH1A1 P00352 4/20 0.55
MAPK1 P28482 1/20 0.55
CYP1A2 P05177 2/20 0.54
NPC1 O15118 2/20 0.53
CYP2C9 P11712 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10970617 0.88 RAB9A (0.85) RAB9APOLBNR4A1GAAKMT2A
SCHEMBL5541810 0.86 F2R (0.61) F2RMAPTALDH1A1
SCHEMBL11863928 0.82 RAB9A (0.70) RAB9APOLBNR4A1GAAKMT2A
SCHEMBL11524019 0.81 RAB9A (0.74) RAB9APOLBNR4A1GAAKMT2A
SCHEMBL11871574 0.81 RAB9A (0.74) RAB9APOLBNR4A1GAAKMT2A
SCHEMBL13856564 0.81 POLB (1.00) RAB9APOLBNR4A1GAAKMT2A
SCHEMBL6360996 0.81 RAB9A (0.69) RAB9APOLBNR4A1GAAKMT2A
SCHEMBL2502058 0.81 RAB9A (0.69) RAB9APOLBNR4A1GAAKMT2A
Hydrochloric Acid SCHEMBL23721867 0.80 RAB9A (0.67) RAB9APOLBNR4A1GAAKMT2A
SCHEMBL2608527 0.80 KMT2A (0.77) RAB9APOLBNR4A1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RAB9A 2824/4885POLB 1637/4885NR4A1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.